Chronic Myelogenous Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

Rochester scientists propose new reason why acute myeloid leukemia is so difficult to cure

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Cancer-associated inflammation boosts ADAR1 enzyme activity

Cancer-associated inflammation boosts ADAR1 enzyme activity

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

TKI-resistant human leukemia stem cells are the source of genomic instability

TKI-resistant human leukemia stem cells are the source of genomic instability

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Ponatinib offers new hope in drug-resistant leukemia

Ponatinib offers new hope in drug-resistant leukemia

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

FDA accepts ARIAD’s ponatinib NDA for filing

FDA accepts ARIAD’s ponatinib NDA for filing

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan